Steris to acquire Xodus Medical in a $2.1 billion cash deal

Steris plc announced a definitive agreement to buy Xodus Medical for $2.1 billion, with a net purchase price of about $1.8 billion after expected cash tax benefits. The transaction includes up to $150 million of performance‑based earnout payments and is slated to close by 31 December 2026, subject to regulatory approval. Xodus projects 2026 revenue of $245 million and adjusted EBIT of $135 million, adding to Steris’s consumables portfolio.

TipRanks analysts rate STE as a Buy and set a $269 price target, citing the acquisition’s accretive potential and Steris’s strong financial quality. The debt‑financed deal will increase leverage but is expected to boost earnings per share from 2027 onward.

  • 1Steris agreed to acquire Xodus Medical for $2.1 billion in cash.
  • 2The net purchase price is reduced to approximately $1.8 billion after cash tax benefits of roughly $300 million.
  • 3Up to $150 million of additional earnout consideration is tied to Xodus performance targets in calendar 2028.
  • 4The acquisition is expected to close by 31 December 2026, pending regulatory approvals.
  • 5Xodus projects 2026 revenue of $245 million.
  • 6Xodus projects adjusted EBIT of $135 million for 2026.

Sources